In ETNA VTA Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries, Cohen et al. report the results of a non-interventional drug utilisation study of edoxaban and conclude that these data reinforce the largely appropriate use of edoxaban in clinical practice [1]. This report is part of the ETNA-VTA Europe post-authorisation safety study (PASS) included by the pharmaceutical company in the Risk Management Plan (RMP) of the product at the time of its marketing authorisation application [2].
